NEW USE OF 1- (5-CYANOINDOL-3-IL) BUTIL) -4- (2-CARBAMOILBENZOFURAN-5-IL) -PIPERAZINE AND ITS PHYSIOLOGICALLY ACCEPTABLE SALTS FOR THE TREATMENT OF BIPOLAR DISORDERS AND MANIA.

摘要

Use of 1- [4- (5-Cyanoindole-3-yl) butyl] -4- (2-carbamoylbenzofuran-5-yl) -piperazine or a physiologically acceptable salt thereof in the preparation of a medicament for the treatment of bipolar disorders A typical clinical study for bipolar disorders and / or mania is described. Twenty (20) male or female patients between the ages of 18 and 65 who suffer from an acute hypomanic episode as part of a Bipolar II Disorder, as diagnosed by DSM-IV, were treated for a period of three weeks either with 1- [4- (5-Cyanoindole-3-yl) butyl] -4- (2-carbamoylbenzofuran-5-yl) -piperazine either with one of its physiologically acceptable salts or with lithium according to a double-blind model. 5-yl) -piperazine or one of its physiologically acceptable salts exhibits or not acute antimanic properties, prior to a long-term prophylaxis study.